Media & Resources

Vaccine well tolerated and demonstrated immunogenicity but did not provide protection against TB recurrence; participants being informed; further analysis continues.

In this episode of Meet the Scientist, IAVI's podcast series, we explore the pivotal significance of community engagement in global collaborative research.

Trial will stop vaccinations due to lack of efficacy.

This year’s Union Conference set the scene for what could be the biggest year to date for tuberculosis (TB) vaccines.

“Science, when it is inclusive, becomes a powerful tool for change,” says IAVI’s Monica Kuteesa.

Global Forum on TB Vaccines will take place October 8-10, 2024 — the first time the meeting will be hosted in the Americas, coming at a time of renewed attention to TB vaccine research and development.

The following commitments must be prioritized by Heads of State and Governments to accelerate the development and delivery of the new tools that are urgently needed to end TB.

New study of nearly 4,000 people of African ancestries led to identification of gene inhibiting HIV replication.